Answers are grounded in this paper and cite their sources.
Interferon-β is the first approved treatment for relapsing multiple sclerosis. Although generally well tolerated, it is sometimes associated with cutaneous reactions at the injection site. To decrease local side effects, it has been suggested that injection sites in the belly, the thigh, and the arms are regularly changed. These cutaneous reactions range from slight erythema to necrosis. We report the first mononeuropathy associated with local adverse reaction after interferon-β injection. A 39 year old woman had a 15 year history of multiple sclerosis, and a 3 year history of secondary progressive phase (EDSS=6). She had been treated for 3 years with …
No takes yet. Share an insight, caveat, or question.
Alain Créange (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: